MPR Weekly Dose Podcast 72

This week we have new study data on the real-world effectiveness of the Pfizer-BioNTech vaccine; The number of Americans who are completing both vaccine doses; A vaccine trial that has started in children; Approval in acute bacterial skin and skin structure infections; And results from the tocilizumab-remdesivir combo trial.

MPR Weekly Dose Podcast 71

This week it’s all COVID related news; There’s new CDC guidance for those who are vaccinated; A first over-the-counter test that doesn’t require a prescription; Nasopharyngeal povidone iodine and the combo of Bamlanivimab-Etesevimab is assessed; And there’s reports of vaccine local reactions.

MPR Weekly Dose Podcast 70

This week we have news of an indication for the cancer treatment, Keytruda, being withdrawn; Janssen’s single dose vaccine gains Emergency Use Authorization; There’s findings on the effectiveness of ivermectin as a therapy for mild COVID-19; And devices to treat migraine and prevention of sub-concussive head impacts are authorized for marketing.

MPR Weekly Dose Podcast 69

An FDA warning to pharma company regarding their promo material; Entresto’s approval is expanded; There’s approvals in homozygous familial hypercholesterolemia and chronic inflammatory demyelinating polyneuropathy; And a migraine device is OK’d for teens.

MPR Weekly Dose Podcast Episode 66

On this week’s pod: The Moderna vaccine and what we know about its effectiveness against emerging variants; Merck ends it’s development of two vaccines; Two separate treatment combos show promise in reducing hospitalizations and preventing COVID-19, respectively; And the FDA approve a new treatment for lupus nephritis.

MPR Weekly Dose Podcast Episode 65

On this week’s MPR pod we take a look at the current status of Johnson & Johnson’s COVID-19 vaccine candidate; Considerations in assessing blood donors during pandemic times; A newly approved drug to treat heart failure; Promising results for a potential Alzheimer treatment; And changes declared for vinca alkaloid labeling.

MPR Weekly Dose Podcast Episode 64

This week we have news of the neutralizing response of the Pfizer-BioNTech vaccine to the new COVID-19 variant; A trial investigated ravulizumab in adults with severe COVID is halted; A rapid blood test for concussions gets the all clear; A novel treatment for chronic kidney disease in patients with type 2 diabetes; And the drug manufacturer Fresenius Kabi announces a voluntary recall of one lot of an NSAID treatment.

MPR Weekly Dose Podcast Episode 63

On the first MPR pod of 2021 we cover the latest COVID-19 vaccine news including admin. scheduling and production; A diagnostics test that may be giving false negative results; Bristol Myers Squibb withdraws an indication for Opdivo; And experts vote on the best diets for 2021.